0001193125-26-197777
SEC filingCerus achieved near-breakeven operations in Q1 2026, with revenue growth and lower interest expense driving a 79% reduction in net loss. The company approaches profitability while investing in capacity expansion ahead of the BARDA contract conclusion.
Cerus demonstrated sustained commercial progress in Q1 2026, with revenue increasing 9.8% to $53.7 million compared to $48.9 million in the prior year period. This growth was primarily driven by sales volume increases in disposable platelet kit sales and IFC sales to U.S. customers. The company continues to invest in capital equipment and capacity expansion with suppliers to meet growing demand and support future gross margin expansion.
The most significant development this quarter was the near-elimination of operating losses. Operating income improved to -$354,000, a 94% improvement from the -$5.9 million operating loss recorded in Q1 2025. This represents a pivotal shift toward operating breakeven, achieved through improved operating leverage as revenue growth outpaced cost increases. The operating margin improved substantially, reflecting the company's progress on its path to profitability.
Net loss narrowed 79% to -$1.6 million, compared to -$7.7 million in the prior year period. This improvement was supported by a decrease in interest expense, resulting from lower interest rates on the company's Term Loan. The reduced interest burden, combined with the operating improvements, drove diluted EPS to -$0.01 compared to -$0.04 in Q1 2025.
Free cash flow was -$3.3 million for the quarter, reflecting net cash used in operating activities of -$3.0 million and capital expenditures of $233,000. The company noted that capital requirements will continue to include investments in capital purchases to support ongoing studies and manufacturing capacity expansion. Management acknowledged that these projects may cost more than anticipated or may be delayed, potentially affecting expected returns on investment.